Drug Profile
Doxorubicin - Vivesto
Alternative Names: DoxophosLatest Information Update: 10 Apr 2023
Price :
$50
*
At a glance
- Originator Oasmia Pharmaceutical
- Developer Vivesto
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Acute myeloid leukaemia; Breast cancer; Endometrial cancer; Ewing's sarcoma; Gastric cancer; Germ cell cancer; Head and neck cancer; Hodgkin's disease; Leukaemia; Lung cancer; Multiple myeloma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Rhabdomyosarcoma; Soft tissue sarcoma; Thyroid cancer; Wilms' tumour
- Preregistration Cancer
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for preclinical development in Cancer in Sweden (IV)
- 20 Nov 2018 Oasmia Pharmaceutical receives patent allowance for 'nanotech method to produce novel pharmaceutical formulations with XR17 nanotechnology platform' in USA
- 16 Aug 2017 Chemical structure information added